ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1355 National Cancer Institute Html en Rectal Cancer Treatment (PDQ®)–Health Professional Version Expert-reviewed information summary about the treatment of rectal cancer.
metastatic colorectal carcinoma0.354846
hepatic colorectal metastases0.223514
recurrent rectal cancer0.223407
Engl J Med0.263348
Ann Surg0.278325
colorectal cancer risk0.276481
asymptomatic colorectal cancer0.241606
colorectal cancer surgery0.262375
metastatic colorectal cancer0.610251
adjuvant rectal cancer0.215149
colorectal cancer0.902264
randomized trial0.206269
patients0.22566
progressive colorectal cancer0.233252
pT3-pT4 colorectal cancer0.254826
Clin Cancer Res0.224834
refractory metastatic colorectal0.227594
malignant colorectal adenomas0.207762
et al.0.485182
familial colorectal cancer0.266438
colorectal liver metastases0.255119
measurable colorectal cancer0.232282
Dis Colon Rectum0.282416
PUBMED Abstract0.3294
untreated metastatic colorectal0.230109
colorectal hepatic metastases0.221405
advanced colorectal cancer0.352094
irinotecan-refractory metastatic colorectal0.231657
Colorectal lung metastases0.222615
advanced colorectal carcinoma0.23983
recurrent colorectal cancer0.262817
Surg Oncol0.226556
colorectal cancer incidence0.264939
colorectal cancer present0.264636
colorectal cancer disparities0.265307
colorectal cancer group0.277657
colorectal cancer rates0.265187
Colorectal Study Group0.21517
Abstract0.47664
colon cancer0.223051
Clin Oncol0.752938
Colorectal cancer follow-up0.250811
liver-limited metastatic colorectal0.225511
Oncol Biol Phys0.206575
dutch colorectal cancer0.274376
Clin Colorectal Cancer0.277838
Cancer J Clin0.227264
colorectal carcinoma metastases0.224249
CLICK HERE
1369 National Cancer Institute Html en Oral Cavity and Oropharyngeal Cancer Screening (PDQ®)–Health Professional Version Expert-reviewed information summary about tests used to detect or screen for oral cancer.
oral examination0.527557
primary screening tool0.417249
squamous cell tumors.0.370971
one-time oral cancer0.520022
systematic oral cavity0.508919
United States0.382344
follow-up period0.371029
sole randomized trial0.365707
physical examination0.446254
cause-specific mortality benefit0.39145
opportunistic screening0.371936
control group0.369767
short follow-up period0.359545
earlier stage cancers0.419364
randomized controlled trials0.375895
oral visual screening0.601987
simple hand-held device0.363139
oral cancer mortality0.59501
premalignant lesions0.420448
oral visual examination0.580404
premalignant oral lesions.0.561468
statistically significant result0.355967
toluidine blue staining0.36957
direct fluorescence visualization0.371807
blue placebo dye.0.359062
oral cancer0.97737
oral/pharyngeal cancers0.364948
oral surgery0.457512
oral cancers0.781555
15-year follow-up period0.369337
overall annual incidence0.409124
overall oral cancers0.566597
routine examination0.355451
screening group0.361703
subclinical high-risk fields0.375561
oral cancer examination.0.562099
positive predictive values0.349612
mortality hazard ratios0.399552
population-based screening programs0.456558
better health outcomes.0.355075
oral cavity0.532106
positive test rates0.356123
periodic health examination0.447578
oral cancer examination0.728118
screening setting0.362271
screening rounds0.355833
cause–specific mortality rate0.408751
CLICK HERE
1770 National Cancer Institute Html es Prurito (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del prurito (picazón en la piel) como complicación del cáncer o su tratamiento. Se consideran los abordajes de manejo y tratamiento del prurito.
haemodialysis patients0.476654
Section XII0.477073
Rubenstein E0.559292
Sin embargo0.803552
Scientific American Medicine0.676981
categoría farmacológica medicamento0.526417
Am Acad Dermatol0.571569
Clin Res0.479277
Wolff K0.536775
Acad Dermatol Venereol0.493209
Farber EM0.55456
patients with atopic0.550773
Cancer Nursing0.471101
PDQ Prurito0.665745
Dermatol Venereol Leprol0.6251
with atopic dermatitis0.566467
toxina botulínica0.473345
reacciones cutáneas0.538217
patients with0.621762
chronic idiopathic0.533598
Pain Symptom Manage0.649291
neuropathic pruritus0.513717
Scientific American0.875762
Oncol Nurs Forum0.782558
Malignant cutaneous tumors0.546882
Dosis Comentarios Referencias0.53479
General Medicine0.52531
terminal cancer patient0.535978
All Free Clear0.515267
Dermatol Venereol0.632286
farmacológica medicamento dosis0.550466
Clinical aspects0.477546
Medicamento Dosis Comentarios0.541353
Acta Derm Venereol0.979711
Eisen AZ0.543793
New York0.832579
patients receiving0.483634
Yosipovitch G0.516371
mg diarios comenzar0.507465
Abel EA0.553787
Enterostomal Ther0.474722
sistema nervioso central0.522009
pruritus relief with0.489446
policitemia vera0.673444
Dermatol Ther0.602936
Fitzpatrick TB0.546636
Federman DD0.567864
Bernhard JD0.556935
chronic pruritus0.522206
CLICK HERE
1843 National Cancer Institute Html es Tratamiento del cáncer de vesícula biliar (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento del cáncer de vesícula biliar.
gemcitabina vs0.562266
Compton CC0.670359
Tsukada K0.846255
Surg Oncol Clin0.680412
situ carcinoma0.687891
accessed october0.566163
Trimodality therapy0.564056
American Cancer Society0.950284
7th ed0.669585
Estadio II–IV0.581785
Chijiiwa K0.675106
Surgical indications0.564187
Instituto Nacional0.7169
Primary carcinoma0.710358
clasificación patológica t20.60477
Uchida K0.58031
enfermedad t20.580737
Arch Surg0.626332
Inapparent carcinoma0.891598
determinados pacientes0.681197
fármacos radiosensibilizadores0.863769
biliary tract0.652373
radical second operation0.814041
Expandable metal stents0.585727
estadio iv0.572834
Cancer Facts0.649725
surgical resection0.561157
Shoup M0.562495
Am Surg0.635005
Cancer Staging Manual0.913061
National Cancer Institute0.633613
Surg Oncol0.770159
from carcinoma0.694816
PDQ Tratamiento0.671094
New York0.64622
second operation after0.820352
tumor dissemination0.618784
Physician Data Query0.581575
Radiation therapy0.568753
ganglios linfáticos n10.740227
Yoshida K0.701223
estadio focal iia0.6289
Byrd DR0.659361
after simple cholecystectomy0.807902
Tis Carcinoma0.710719
Am Coll Surg0.657212
T)a aReproducción0.561453
AJCC Cancer Staging0.929134
Edge SB0.670645
CLICK HERE
1884 National Cancer Institute Html es Tratamiento de las neoplasias de células plasmáticas (incluso mieloma múltiple) (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento de las neoplasias de células plasmáticas (incluso mieloma múltiple).
mieloma múltiple grupo0.317462
multicentre randomized study0.314956
Rajkumar SV0.360993
Durie BG0.317277
Dispenzieri A0.381536
primary plasma cell0.32094
Lacy MQ0.31455
extramedullary plasmacytoma0.321972
light chain0.421207
Myeloma Study Group0.325182
versus deferred treatment0.314362
plasma cell0.333759
monoclonal gammopathies0.324288
Radiat Oncol Biol0.320101
multiple myeloma0.968571
systemic amyloidosis0.315374
stem cell transplantation0.348134
International Myeloma Working0.450729
células plasmáticas tipo0.324338
proteína m0.360491
Rosiñol L0.316442
patients with0.434191
patients with primary0.318338
plasma cell leukemia0.319942
UK Myeloma Forum0.317407
células madre0.338769
Myeloma Working Group0.450073
International Blood0.317358
primary systemic amyloidosis0.314303
peripheral blood stem0.321195
células plasmáticas oligosecretoras0.325603
Therneau TM0.332031
monoclonal gammopathy0.501114
Dimopoulos MA0.326344
Kumar SK0.315489
lesiones óseas0.347582
light chain amyloidosis0.337292
International Staging System0.324252
monoclonal sérica tipo0.317411
Kyle RA0.395277
Clin Oncol0.474276
myeloma with0.317498
Oncol Biol Phys0.320425
mieloma múltiple estadio0.31799
Nordic Myeloma Study0.324636
with newly diagnosed0.31487
células plasmáticas neoplasia0.324857
mieloma múltiple igg0.323238
patients with newly0.318559
CLICK HERE
1912 National Cancer Institute Html es Tratamiento de la leucemia mieloide aguda y otras neoplasias mieloides malignas infantiles (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento del cáncer de la leucemia mieloide aguda y otras neoplasias mieloides malignas infantiles.
síndromes mielodisplásicos.Quimioterapia0.302945
linfocítica aguda0.307126
siguientes procedimientos0.33161
siguientes aspectos0.303162
Neurofibromatosis tipo0.303799
células madre formadoras0.308269
siguientes especialistas0.302945
hueso compacto0.308024
neoplasias mieloides0.310246
célula madre mieloide0.324347
Bultos indoloros0.302618
líquido cefalorraquídeo0.326401
leucemia mielomonocítica0.41887
Instituto Nacional0.305639
célula madre linfoide0.318549
siguientes problemas0.302781
leucemia mielógena0.419565
neoplasias mielodisplásicas0.302899
LMA recién0.316713
cáncer regrese).El0.307025
madre mieloides0.328575
células madre mieloides0.318746
leucemia promielocítica aguda0.371662
células madre0.977959
leucemia mielógena aguda0.321693
leucemia aguda0.310888
leucemia linfoblástica aguda0.335277
síndromes mielodisplásicos0.43219
enlace drugs approved0.308769
Acute Myeloid Leukemia0.309058
infantil recidivante0.30755
Sudores nocturnos0.302372
efectos tardíos0.309904
médula ósea.Leucemia mielógena0.31318
células cancerosas.El gemtuzumab0.309349
punción espinal.Ampliar0.30255
leucemia granulocítica aguda0.320187
PDQ Tratamiento0.305949
blastocitos mieloides0.303489
tirosina cinasa0.339619
sistema nervioso central0.381371
leucemia mieloblástica aguda0.320188
Physician Data Query0.305829
enfermedades mieloides0.315553
SMD)Algunos tratamientos0.302284
revés.La prueba0.301997
leucemia mieloide aguda0.981978
célula madre0.354129
siguientes sumarios0.305018
CLICK HERE
2070 National Cancer Institute Html es Inhibidores de la angiogénesis Hoja informativa que describe el proceso de eliminación de suministro de sangre a los tumores. Incluye una lista de los cánceres en los que se está probando este enfoque.
vasos sanguíneos resultantes0.32417
NCI de estudios0.304711
llamadas metástasis0.305878
posibles efectos0.304824
Drug Administration0.306756
células renales0.307581
angiogénesis efectos0.326284
Estados Unidos0.315596
vasos sanguíneos0.986577
CLICK HERE
3605 National Cancer Institute Html en Enhancing Drug Discovery and Development The discovery and development of new therapeutic agents for cancer is essential for continued progress against the disease. Historically, NCI has played a vital role in cancer drug discovery and development, and, today, that role continues. Frequently, NCI’s drug development efforts focus on unmet needs that are not being adequately addressed by the private sector.
human tumor cell0.493589
Developmental Therapeutics Program0.373741
cell lines0.756764
corresponding cancer types0.401362
primary cancer cells0.471158
drug discovery0.918943
cell line panel0.382826
long-term cell cultures0.381121
drug screening0.363881
development activities0.393342
human cancer models0.633791
human tumor samples0.437784
precision medicine0.432081
congressionally mandated initiative0.360908
human cancer cell0.54738
drug resistance0.374751
tyrosine kinase inhibitor0.365397
drug development efforts0.451048
potential anticancer agents0.404376
traditional cell lines0.391913
parental tumors0.388039
routine cancer care0.38291
Cancer Treatment0.353066
cancer cells0.647891
cancer cell lines0.473566
new human cancer0.517038
cancer cell biology0.425139
NCI Experimental Therapeutics0.397544
tumor sections0.354283
cell line screen0.52167
largest cancer pharmacology0.402164
cell culture techniques0.37598
NCI-60 cell line0.515114
drug discovery program0.435482
NIH Clinical Center0.354806
cancer stem cells0.444759
anticancer drug discovery0.568944
biologic agent discovery0.381604
new therapeutic agents0.383079
Cancer Chemotherapy National0.425183
NCI’s anticancer0.350161
clinical development resources0.397358
NCI’s drug0.370038
original tumor0.350461
normal cell counterparts0.370786
cancer drug discovery0.678381
Human cancer cells0.468312
multiple cell types0.380725
tumor microenvironment0.401449
CLICK HERE
16680 National Cancer Institute Html en Cancer Moonshot℠ Implementation Implementation teams are considering multiple ways to fund new programs as well as expansions of ongoing efforts to advance the goals of the Cancer Moonshot.
Cancer Moonshot-related research0.688251
ongoing efforts0.579887
funding opportunity announcements0.69197
authorization0.517804
oversight0.515337
Cancer Moonshot portfolio0.716496
academia0.515431
Cancer Moonshot goals0.684682
Century Cures Act0.85793
expansions0.51624
implementation teams0.716347
email Partnerships_CancerMoonshot0.582993
list0.516345
Scientific Advisors0.584259
important role0.585193
longer-term scientific initiatives0.700429
research opportunities0.75591
multiple ways0.591922
private sector0.587499
Cancer Moonshot0.987984
Cancer Moonshot initiatives0.68956
concept proposals0.656557
automatic email0.583279
receipt0.519207
NCI intramural staff0.745934
cancer research community0.682183
NCI extramural program0.749793
Program Leadership Committee0.655079
potential partners0.586537
available FOAs0.62206
NCI’s Board0.674346
NIH institutes0.582819
existing funds0.59672
new research opportunities0.683581
21st Century Cures0.861565
scientific opportunities0.594628
Blue Ribbon Panel0.846596
BRP recommendation0.740701
working groups0.588634
new funding concepts0.653803
BRP recommendations0.654047
Public-private partnerships0.590589
Cancer Moonshot implementation0.678145
NCI advisory committees0.753041
NCI’s Scientific0.67691
report0.517155
new programs0.586358
funding mechanism0.587953
CLICK HERE
16708 National Cancer Institute Html en ALCHEMIST (The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials): Questions and Answers ALCHEMIST represents three integrated, precision medicine trials that are designed to identify people with early-stage lung cancer who have tumors that harbor certain uncommon genetic changes and evaluate whether drug treatments targeted against those mol
certain genetic alterations0.511031
ALK gene rearrangement0.86792
specific genetic alterations0.510493
lung cancer0.965003
ALK genetic alterations0.561732
component trials0.510228
National Clinical Trials0.497396
clinical trials0.62346
early-stage lung cancer0.707269
EGFR gene mutation0.628828
best treatment approach0.483241
lung cancers0.649896
ALK Treatment component0.564764
ECOG-ACRIN Cancer Research0.536673
ALK rearrangement0.515701
non-small cell lung0.519586
Adjuvant Lung Cancer0.554841
EGFR gene mutations0.510846
uncommon genetic changes0.484048
ALCHEMIST treatment trial0.613717
new treatment approaches0.481108
lung carcinoid tumors0.539366
early-stage lung cancers0.57159
appropriate ALCHEMIST treatment0.663904
ALK gene0.888431
precision medicine trials0.560161
tumor tissue0.58358
United States0.513049
Dana-Farber Cancer Institute0.495276
ALK alterations0.531283
small cell lung0.519071
National Cancer Institute0.484824
ALCHEMIST study0.594796
cancer risk characteristics0.487226
EGFR Treatment component0.512344
participants0.568322
ALCHEMIST treatment trials0.868218
genetic alterations0.637424
complete surgical removal0.527484
Cancer Research Group0.536403
early-stage lung adenocarcinoma0.54246
cell lung cancer0.575738
Cancer Genomics0.482098
FDA-approved Vysis ALK0.52631
ALCHEMIST screening trial0.716569
ALCHEMIST trials0.680442
standard therapy0.505511
Clinical Trials Agreement0.491455
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.